Currently, there are 49.61M common shares owned by the public and among those 45.93M shares have been available to trade.
The company’s stock has a 5-day price change of 16.37% and -2.01% over the past three months. MBIO shares are trading 20.90% year to date (YTD), with the 12-month market performance down to -84.15% lower. It has a 12-month low price of $0.13 and touched a high of $1.53 over the same period. MBIO has an average intraday trading volume of 7.47 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.92%, -1.09%, and -35.11% respectively.
Institutional ownership of Mustang Bio Inc (NASDAQ: MBIO) shares accounts for 5.72% of the company’s 49.61M shares outstanding.
It has a market capitalization of $11.09M and a beta (3y monthly) value of 1.77. The earnings-per-share (ttm) stands at -$1.79. Price movements for the stock have been influenced by the stock’s volatility, which stands at 42.68% over the week and 17.69% over the month.
Looking at the support for the MBIO, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on May 18, 2021, with the firm’s price target at $11. B. Riley FBR coverage for the Mustang Bio Inc (MBIO) stock in a research note released on October 02, 2020 offered a Buy rating with a price target of $9. Cantor Fitzgerald was of a view on November 20, 2019 that the stock is Overweight, while H.C. Wainwright gave the stock Buy rating on August 13, 2019, issuing a price target of $7. Cantor Fitzgerald on their part issued Overweight rating on June 21, 2019.
